Deciphering immuno biomarkers of HTLV infection and HIV/HTLV coinfection to improve patient treatments

• Grant number: 20/05758-2
• Support Opportunities: Regular Research Grants
• Duration: December 01, 2020 - November 30, 2022
• Field of knowledge: Biological Sciences - Immunology - Applied Immunology
• Convênio/Acordo: Université de Lyon (UDL)
• Principal Investigator: Jorge Simão do Rosário Casseb
• Grantee: Jorge Simão do Rosário Casseb
• Principal researcher abroad: Dutartre Hélène
• Institution abroad: Universidad de Lleida (UdL), Spain
• Host Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• Associated scholarship(s): 22/02068-0 - Deciphering immunobiomarkers of HTLV infection and HIV/HTLV coinfection to improve patient treatments, BP.TT

Abstract

The HTLV-1 human oncogenic retrovirus infects 10-20 million worldwide, with more than 1 million carriers living in Brazil [1]. Five to 10 percent of infected individuals will develop an HTLV-1 associated disease: Adult T cell Leukemia (ATL), an aggressive lymphoproliferation of CD4+ T cells of poor prognosis (mean survival time of 6 months in the acute form), or HTLV-1 associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP), a chronic neuro-degenerative disease. Several mechanisms lead to HTLV-1 associated disease progression, the first being the oncogenic properties of Tax and HBZ viral proteins. (AU)